产前皮质类固醇的使用和儿童呼吸道疾病:回归不连续性研究
Jennifer A Hutcheon1, Sam Harper2, M Claire Cordingley1
1Department of Obstetrics & Gynaecology, University of British Columbia, Vancouver, Canada.
概括
常规的产前皮质类固醇似乎不会增加婴儿下呼吸道感染或儿童喘的风险. 这项研究发现,皮质类固醇暴露与儿童的这些呼吸道结果之间没有显著的关联.
科学领域:
- 产科和妇科 产科和妇科
- 儿科 儿科 儿科
- 流行病学 流行病学
背景情况:
- 产前皮质类固醇用于孕妇,以促进胎儿肺部成熟.
- 人们担心,常规的产前皮质类固醇使用可能会对呼吸系统产生长期影响.
研究的目的:
- 调查常规产前皮质类固醇给药与婴儿下呼吸道感染和儿童喘风险之间的关联.
主要方法:
- 在加拿大不列颠哥伦比亚省进行了一项基于人口的相关队列研究.
- 一个回归不连续性设计分析了怀孕31周至36周之间的单独怀孕,并比较了34周怀孕切断期对皮质类固醇施用的结果.
- 逻辑二项回归模型被用来评估下呼吸道感染住院和喘诊断的风险,直到18岁.
主要成果:
- 该研究包括21,965名儿童,其中1.9%因下呼吸道感染住院,10.4%被诊断患有喘.
- 常规产前皮质类固醇的使用与婴儿下呼吸道感染没有显著的关联 (风险比=0.95;95%CI:0.61,1.37).
- 在产前皮质类固醇和儿童喘之间没有发现显著的关联 (比率比率=1.08;95% CI:0.88,1.24).
结论:
- 结果表明,没有证据表明,例行产前皮质类固醇的使用会影响婴儿下呼吸道感染或儿童喘的风险.
- 这项研究有助于了解产前皮质类固醇对儿童长期呼吸系统健康的安全性.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
228
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
228
COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
246
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
246
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma: Pathogenesis and Management
371
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
371
Antiasthma Drugs: Leukotriene Modifiers
253
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
253


